ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Active, not recruiting

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Bimatoprost (SR)

First Posted Date: 2019-02-22

Last Posted Date: 2024-02-13

Lead Sponsor: AbbVie

Target Recruit Count: 515

Registration Number: NCT03850782

Locations: 🇺🇸
Fraser Eye Center /ID# 235790, Fraser, Michigan, United States
🇺🇸
AMA Eyes Research Institute /ID# 235542, Marysville, Ohio, United States
🇧🇬
MHAT Hadzhi Dimitar /ID# 238248, Sliven, Bulgaria

and more 105 locations

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Acute Myeloid Leukemia
Multiple Myeloma
Non-Hodgkin's Lymphoma
Acute Lymphoblastic Leukemia
Cancer

Interventions: Drug: Venetoclax

First Posted Date: 2019-02-18

Last Posted Date: 2024-12-06

Lead Sponsor: AbbVie

Target Recruit Count: 165

Registration Number: NCT03844048

Locations: 🇯🇵
Duplicate_National Hospital Organization Mito Medical Center /ID# 241986, Higashi Ibaraki-gun, Ibaraki, Japan
🇺🇸
University of Arizona Cancer Center - Tucson /ID# 210548, Tucson, Arizona, United States
🇺🇸
UCLA Santa Monica Hematology Oncology /ID# 210551, Los Angeles, California, United States

and more 53 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Phase 2

Completed

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: Placebo for ABBV-3373
Drug: ABBV-3373
Drug: Adalimumab
Drug: Placebo for adalimumab

First Posted Date: 2019-01-30

Last Posted Date: 2021-07-19

Lead Sponsor: AbbVie

Target Recruit Count: 48

Registration Number: NCT03823391

Locations: 🇺🇸
PCCR Solution /ID# 215457, Colleyville, Texas, United States
🇺🇸
C.V. Mehta MD, Med Corporation /ID# 213068, Hemet, California, United States
🇺🇸
Robin K. Dore MD, Inc /ID# 213045, Tustin, California, United States

and more 27 locations

A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

Phase 2

Terminated

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: Elsubrutinib
Drug: Placebo for upadacitinib
Drug: Placebo for elsubrutinib
Drug: Upadacitinib

First Posted Date: 2019-01-30

Last Posted Date: 2021-09-16

Lead Sponsor: AbbVie

Target Recruit Count: 97

Registration Number: NCT03823378

Locations: 🇵🇱
ClinicMed Daniluk, Nowak Sp.j. /ID# 212578, Białystok, Podlaskie, Poland
🇭🇺
CMED Rehabilitacios es Diagnosztikai Kozpont /ID# 208188, Szekesfehervar, Hungary
🇵🇱
NBR Polska /ID# 209904, Warsaw, Mazowieckie, Poland

and more 27 locations

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors Cancer

Interventions: Drug: Livmoniplimab
Drug: Budigalimab

First Posted Date: 2019-01-30

Last Posted Date: 2025-01-08

Lead Sponsor: AbbVie

Target Recruit Count: 362

Registration Number: NCT03821935

Locations: 🇪🇸
Hospital Clinico Universitario de Valencia /ID# 221107, Valencia, Spain
🇺🇸
University of Washington Medical Center /ID# 268854, Seattle, Washington, United States
🇺🇸
Highlands Oncology Group, PA /ID# 218942, Springdale, Arkansas, United States

and more 51 locations

A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 1

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: ABBV-927
Drug: ABBV-368
Drug: ABBV-181

First Posted Date: 2019-01-28

Last Posted Date: 2020-12-31

Lead Sponsor: AbbVie

Target Recruit Count: 3

Registration Number: NCT03818542

Locations: 🇺🇸
Massachusetts General Hospital /ID# 207392, Boston, Massachusetts, United States
🇺🇸
University of Michigan /ID# 210181, Ann Arbor, Michigan, United States
🇺🇸
MD Anderson Cancer Center /ID# 208749, Houston, Texas, United States

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Non-Hodgkin's Lymphoma
Diffuse Large B-cell Lymphoma

Interventions: Drug: Venetoclax
Drug: AMG 176

First Posted Date: 2019-01-09

Last Posted Date: 2021-12-07

Lead Sponsor: AbbVie

Target Recruit Count: 9

Registration Number: NCT03797261

Locations: 🇺🇸
USC Norris Cancer Center /ID# 207396, Los Angeles, California, United States
🇺🇸
Duplicate_Dana-Farber Cancer Institute /ID# 207367, Boston, Massachusetts, United States
🇦🇺
Calvary Mater Newcastle /ID# 211455, Waratah, New South Wales, Australia

and more 14 locations

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

Phase 2

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: venetoclax
Drug: lenalidomide
Drug: dexamethasone

First Posted Date: 2018-12-24

Last Posted Date: 2019-08-28

Lead Sponsor: AbbVie

Registration Number: NCT03785184

Locations: 🇦🇺
St. Vincents Hosp Melbourne /ID# 210266, Fitzroy, Victoria, Australia
🇨🇦
Hopital Maisonneuver-Rosemont /ID# 208550, Montreal, Quebec, Canada
🇦🇺
Austin Hospital /ID# 210268, Heidelberg, Victoria, Australia

and more 19 locations

Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)

Phase 2

Completed

Conditions: Post-Operative Atrial Fibrillation

Interventions: Drug: AGN-151607
Drug: Placebo

First Posted Date: 2018-12-19

Last Posted Date: 2024-05-14

Lead Sponsor: AbbVie

Target Recruit Count: 323

Registration Number: NCT03779841

Locations: 🇺🇸
University of Maryland Medical Center /ID# 234352, Baltimore, Maryland, United States
🇦🇹
Medizinische Universitaet Wien /ID# 238259, Vienna, Wien, Austria
🇺🇸
Stanford University School of Med /ID# 236922, Stanford, California, United States

and more 29 locations

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Phase 3

Completed

Conditions: Parkinson's Disease (PD)

Interventions: Drug: ABBV-951

First Posted Date: 2018-12-19

Last Posted Date: 2023-10-23

Lead Sponsor: AbbVie

Target Recruit Count: 244

Registration Number: NCT03781167

Locations: 🇪🇸
Hospital Santa Creu i Sant Pau /ID# 208240, Barcelona, Spain
🇺🇸
Northwestern University Feinberg School of Medicine /ID# 208812, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital /ID# 207993, Boston, Massachusetts, United States

and more 62 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy